Sinry The role of chemotherapy m the palliation of patients with advanced st (IIB and non-small-cel (Souquet et al., 1993) , and chemotherapy remains very much a palliative approach.
The role of chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial.
Some, but not all, recent trials have shown a survival advantage for combination chemotherapy over best supportive care in this condition (Cormier et al., 1982; Rapp et al., 1988; Cartei et al., 1993) , and one has shown chemotherapy to be more cost-effective than supportive care (Jaakkimairn et al., 1990) . Very recently, an overview analysis of seven trials has confirmed a statistically significant survival benefit, but a modest one (Souquet et al., 1993) , and chemotherapy remains very much a palliative approach.
No single chemotherapy regimen has been shown superior to others in the treatment of NSCLC, but best response rates have consistently been achieved with cisplatin-based regimens (Veronesi et al., 1988; Luedke et al., 1990) . The combination of isplatin with mitomycin C and vinblasti has been shown in randomised trials to be one of the most effective regimens (Ruckdeschel et al., 1986) , and this has the advantage over most other combinations of very rarely causing signiicant alopecia (an important consideration for palliative treatment). There is a tendency to use cisplatin in high dosage (100-120mgm-) in many of these regimens, but this is associated with significnt toxicity, including emesis, peripheral neuropathy, nephrotoxicity and high-frequency hearing loss. These problems disappear or are at least very markedly reduced with moderate-dose cisplatin (50mgm-2) and probably without significant reduction in efficacy (Hardy et al., 1989) .
We have therefore developed a moderate-dose cisplatin (P) regimen in combination with mitomycin C (M) and vinblastine (V) (MVP) which is well tolerated with few side-effects (Hardy et al., 1989 Total (%) 17 (15) 59 (54) 19 (17) 15 (14) 110 sion of symptoms during chemotherapy. Details of symptomatic response are given in Table III . Forty-six of the 76 responding patients (61%) had a symptomatic response after only one course of chemotherapy and 73 (96%) after two courses. Thirty of these had a further improvement of symptoms with more treatment. Only three patients who failed to achieve symptomatic relief with two courses of treatment (4%) gained a symptomatic response with further treatment.
Thirty-three of 36 patients (92%) with an objective response to treatment gained symptomatic relief. However, 43 patients (54%) with no change or progressive disease on objective response assessment also gained symptomatic relief.
Those patients who had a symptomatic response to therapy had a significant survival advantage over those who did not (median survival 6 months vs 3 months respectively, P<0.005) (Figure 1 ). Median symptomatic response duration was 15 weeks from start of treatment (range 4-65 weeks).
Toxicity
Overall, treatment with this moderate-dose cisplatin regimen was well tolerated. Haematological toxicty was minimal (Table IV) . Only seven patients (6%) developed WHO grade 3/4 neutropenia, and only four patients (3%) developed grade 3/4 thrombocytopenia. Two patients developed neutropenic fever, but only one of these developed a significnt neutropenic infection (1%). One other patient died in his local hospital of presumed neutropenic sepsis. The most significant adverse effect was emesis, with 22 patients (19%) developing grade 3/4 nausea and vomiting on at least one treatment cycle. Alopecia was minimal, with only three patients (3%) developing signifcant hair loss. Other signicant side-effects including neuropathy and nephrotoxicity were rare (Table V) . Dose reductions and delays Eleven patients (9%) required a 25% dose reduction during chemotherapy. In five cases this was due to a reduction in (Cormier et al., 1982; Rapp et al., 1988; Cartei et al., 1993) . In one of these trials, the total costs of supportive care alone exceeded those of chemotherapy because more in-patient time was required for symptom control (Jaakkimainen et al., 1990) . On the other hand, not all trials have shown a statistically significnt survival benefit (Ganz et al., 1989; Woods et al., 1990; Kaasa et al., 1991) . Very recently, an overview analysis of seven such trials has confirmed an overall reduction in mortality with chemotherapy (Souquet et al., 1993) , but even in the positive trials the survival benefit has been small at around 4-5 months. In addition, chemotherapy is frequently perceived as being expensive and toxic. For these reasons, its role as palliative treatment for NSCLC has remained controversial. Our results from this study belie some of these critiisms. First and most important, this MVP schedule achieves useful symptomatic benefit in around two-thirds of patients. An interim analysis of another large trial has also suggested improvement in tumour-related symptoms following chemotherapy (Cullen, 1993 severe alopecia (3%); for most other schedules this problem is almost universal. In addition, by using cisplatin in moderate dosage, we have abolished the risk of severe druginduced nephro-and neurotoxicity reported in other studies (Ruckdeschel et al., 1986; Rapp et al., 1988) . Third, this is a simple and inexpensive regimen; the drug cost of around £78 per course is up to 10-fold cheaper than some other commonly used chemotherapy schedules in cancer medicine. Most of our patients were treated on an overnight in-patient basis, but the schedule can readily be adapted for day care use.
Have these benefits been gained at the expense of decreased efficacy compared with other more intensive and expensive regimens? Higher dose cisplatin regimens have been advocated for NSCLC (Donnadieu et al., 1991) and at least one early trial showed a survival benefit in responding patients for high vs moderate-dose cisplatin (Gralla et al., 1981 therefore also depend on cost-effectiveness and low treatment-associated morbidity. In this context, we believe that this pragmatic low-risk MVP schedule, with established efficacy and low toxicity, should now be assessed as primary (neoadjuvant) chemotherapy before radical radiotherapy for locally advanced NSCLC in a randomised trial.
